Rheumatoid and Auto-immune

Rheumatoid-arthritis

Autoimmune diseases affect 23.5 million Americans, and that number is rising. Autoimmune diseases are one of the top ten leading causes of death for women under the age of 64.1 In autoimmune diseases, the body undergoes an inappropriate immune response that causes excessive inflammation that becomes destructive to the body.

Psoriasis is a chronic inflammatory skin condition — the most prevalent autoimmune disease in the U.S. affecting about 7.5 million Americans, and it is much more than a cosmetic concern.2 Depending on the severity of psoriasis, it can also cause skin cracking and bleeding, pain, and a significant disruption of quality of life. In addition, psoriasis is associated with increased cardiovascular risk.3-5 Even mild psoriasis may increase the risk of heart attack by up to 29%.6 The chronic inflammation characteristic of psoriasis (and other autoimmune diseases such as rheumatoid arthritis and lupus) puts patients at risk.7, 8 In addition to cardiovascular disease, psoriasis patients are also more likely to suffer from insulin resistance, depression, cancer, osteoporosis, and liver disease — also likely due to chronic inflammation.9-11

 

Nutritional intervention should always be tried first before powerful and potentially dangerous drugs are prescribed.

Conventional treatments for autoimmune diseases suppress the immune system to halt the body’s immune attack on itself. However, this makes the body more susceptible to infections and even cancers — one study found that autoimmune patients with the greatest exposure to immunosuppressive drugs had an almost 5-fold increase in cancer risk.12 The FDA has issued warnings on certain drugs used to treat autoimmune diseases because of increased cancer risk.13 Mild to moderate psoriasis can often be treated with topical medications only — these are safer than systemic medications, but still have significant side effects such as skin thinning, pigmentation changes, bruising easily, stretch marks, redness, and acne. They also may stop working over time.14

Nutrition is a powerful and safe tool for preventing and treating autoimmune diseases. At our Center we give guarantee money back offer for residential treatment for autoimmune diseases like rheumatic arthritis. It takes 15 to 25 days for Complete Cure.

 


References:

1. American Autoimmune Related Disease Association: Autoimmune Statistics [http://www.aarda.org/autoimmune_statistics.php ]
2. About Psoriasis: Statistics.: National Psoriasis Foundation.
3. Gelfand JM, Azfar RS, Mehta NN: Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010;130:919-922.
4. Mehta NN, Yu Y, Pinnelas R, et al: Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011;124:775 e771-776.
5. Dermatologists urge psoriasis patients to be aware of potential link to other serious diseases. In American Academy of Dermatology 70th Annual Meeting; San Diego, CA. 2012
6. Gelfand JM, Neimann AL, Shin DB, et al: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741.
7. Pieringer H, Pichler M: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2011;104:13-26.
8. Alexandroff AB, Pauriah M, Camp RD, et al: More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009;161:1-7.
9. Zanni GR: Psoriasis: issues far more serious than cosmetic. Consult Pharm 2012;27:86-88, 90, 93-86.
10. Mehta NN, Azfar RS, Shin DB, et al: Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006.
11. Davidovici BB, Sattar N, Prinz JC, et al: Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-1796.
12. Asten P, Barrett J, Symmons D: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-1714.
13. Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009. U.S. Food and Drug Administration; 2009.
14. Topical treatments for psoriasis, including steroids.: National Psoriasis Foundation.